Core Insights - Avicanna Inc. reported Q2 2025 results, highlighting growth in its commercial channels and achieving positive adjusted EBITDA for the first half of 2025, indicating operational efficiency and financial discipline [2][5]. Financial Highlights - Revenue for Q2 2025 was $6.16 million, a 1% increase year-over-year, while revenue for the six-month period was $12.48 million, reflecting a 1% decrease compared to the same period in 2024 [5]. - Gross profit for Q2 was $3.13 million, with a gross margin of 51%, and for the six-month period, gross profit totaled $6.73 million with a margin of 54%, up from 47% in the prior-year periods [5]. - Adjusted EBITDA showed a loss of $0.25 million for Q2 but a gain of $0.18 million for the six-month period, marking an improvement from losses of $0.44 million and $0.42 million in the same periods of 2024 [5]. Corporate Highlights - The company expanded its product offerings, ending Q2 with 50 commercial SKUs and 147 listings, representing a 19% increase in SKUs and a 9% increase in listings from Q1 2025 [5]. - Avicanna sold 50,789 units in Q2, a 21% increase compared to the same period in 2024 [5]. - The company announced a sponsorship for a Phase II clinical study on osteoarthritis pain, which is its first placebo-controlled, blinded randomized multicenter trial [5]. - A symposium on cannabinoid-based medicine was held in June 2025, focusing on research and clinical applications, attended by key opinion leaders and healthcare providers [5]. - Avicanna received a new patent from the US Patent and Trademark Office for a topical cannabinoid composition aimed at treating skin conditions [5][6].